Heat shock protein 70 (HSP70) can inhibit apoptosis by neutralizing and interacting with apoptosis-inducing factor (AIF), a mitochondrial flavoprotein that translocates upon apoptosis induction to the nucleus, via the cytosol. Here, we show that only members of the HSP70 family interact with AIF. Systematic deletion mapping revealed the existence of three distinct functional regions in the AIF protein: (1) a region between amino acids 150 and 228 that binds HSP70, (2) a domain between residues 367 and 459 that includes a nuclear localization sequence (NLS) and (3) a C-terminal domain beyond residue 567 required for its chromatin-condensing activity. Deletion of the 150-268 domain completely abolished HSP70 binding and facilitated the nuclear import of AIF, resulting in a gain-of-function phenotype with enhanced AIF-mediated chromatin condensation as compared to wild-type AIF. This gain-of-function phenotype was observed in wild-type control cells (which express low but significant levels of HSP70), yet was lost when AIFD150-268 was introduced into HSP70 knockout cells, underscoring the functional importance of the AIF-HSP70 interaction. Altogether, our data demonstrate that AIF inhibition by HSP70 involves cytosolic retention of AIF. Moreover, it appears that endogenous HSP70 protein levels are sufficiently elevated to modulate the lethal action of AIF.
Introduction
Apoptosis or programmed cell death is responsible for the removal of unwanted or supernumerary cells during development, as well as in adult homeostasis (Jacobson et al., 1997) . Apoptosis is also the predominant form of cell death triggered by cytotoxic drugs in tumour cells (Solary et al., 2000) . In response to multiple proapoptotic signal-transducing pathways , the outer membrane becomes permeabilized, resulting in the release of molecules normally confined to the intermembrane space. Such proteins translocate from the mitochondria to the cytosol in a reaction that is controlled by Bcl2-and Bcl2-related proteins . One of the released intermembrane proteins is cytochrome c, which, once in the cytosol, interacts with apoptotic protease activating factor-1 (Apaf-1), thereby triggering the ATP-dependent oligomerization of Apaf-1 (Li et al., 1997; Hu et al., 1999 ). Oligomerized Apaf-1 then binds to cytosolic procaspase-9, thereby leading to the formation of the so-called apoptosome, the caspase-9 activation complex. Activated caspase-9 then triggers the proteolytic maturation of procaspase-3, setting off activation of the caspase cascade (Li et al., 1997) responsible for the apoptotic cell death.
Another apoptogenic molecule also released from the mitochondria is the flavoprotein apoptosis-inducing factor (AIF). AIF released into the cytosol is imported into the nucleus, where it triggers caspase-independent nuclear changes (Susin et al., 1999; Daugas et al., 2000) . Genetic inactivation of AIF abolishes the first wave of apoptosis indispensable for early embryonic morphogenesis (Joza et al., 2001) . The apoptogenic properties of AIF are conserved throughout evolution from the facultative multicellular organism Dyctiostelium discoideum to Caenorhabditis elegans and mammals (Wang et al., 2002) . AIF is synthesized as a 67 kDa precursor and converted to mature AIF (57 kDa) upon mitochondrial import and removal of the N-terminal mitochondrial localization signal (MLS) (Susin et al., 1999) . Mature AIF is a flavoprotein with weak but significant sequence homology with bacterial oxidoreductases, suggesting that it is a bifunctional protein with a mitochondrial-resident role and an apoptogenic function. Since the flavin adenine dinucleotide (FAD) cofactor is dispensable for the apoptogenic function, but required for the oxidoreductase activity of AIF (Susin et al., 1999; Miramar et al., 2001) , the structural basis for the mitochondrial and ectopic effects of AIF is likely to be entirely different. We have recently shown that AIF has to translocate to the nucleus in order to exert its apoptotic function. Thus, mutations of AIF that abolish its interaction with DNA reduced its nuclear import and curtail its chromatin-condensating activity (Ye et al., 2002) .
Stress-inducible heat shock protein 70 (HSP70) is a prominent cytoprotective factor. Under normal conditions, HSP70 functions as an ATP-dependent chaperon by assisting the folding of newly synthesized proteins and polypeptides, the assembly of multiprotein complexes and the transport of proteins across cellular membranes (Murakami et al., 1988; Beckmann et al., 1990; Shi and Thomas, 1992) . When HSP70 is upregulated by cellular stress or transfection, it inhibits the apoptosis induced by a wide range of insults, a fact that may contribute to the oncogenic transformation mediated by HSP70 (Seo et al., 1996; Volloch and Sherman, 1999) . HSP70 overexpression has been shown to increase the tumorigenicity of cancer cells in rodent models (Jaattela, 1995) . Conversely, HSP70 downregulation is sufficient to kill tumour cells or to facilitate the induction of apoptosis (Nylandsted et al., 2000; Gurbuxani et al., 2001) . The antiapoptotic function of HSP70 involves interactions with several components of the apoptotic machinery. Indeed, HSP70 has been demonstrated to bind to Apaf-1, thereby preventing the recruitment of procaspase-9 to the apoptosome (Beere et al., 2000) . The ATPase domain of HSP70 was described to be necessary for this interaction. We have shown that HSP70 can also inhibit caspaseindependent apoptosis by directly interacting with AIF and thereby neutralizing AIF-induced nuclear modifications. Interestingly, the ATP-binding domain of HSP70 is dispensable for this interaction, suggesting that it is independent of the chaperon function of HSP70. It is noteworthy that endogenous levels of HSP70 seem to be sufficiently high to control AIFmediated apoptosis, because downregulation of HSP70 by an anti-sense construct increases the sensitivity of cells to AIF-mediated killing .
In order to understand the molecular basis of AIF modulation by its endogenous inhibitor HSP70, we constructed deletion mutants of AIF and localized the functional regions involved in HSP70 binding, nuclear translocation and/or apoptosis. We demonstrate that a region between amino acids 150 and 228 of AIF is responsible for HSP70 binding and that this interaction inhibits AIF apoptotic function by blocking its nuclear translocation. A region from amino acids 367 to 459, which includes a consensus nuclear localization sequence (NLS), was found to be required for the nuclear import of AIF. Finally, we defined a C-terminal fragment (amino acids 567-609) necessary for the chromatin-condensing activity of AIF. Using this arsenal of deletion mutants, we produced data that provide new insights into the molecular mechanism of AIF-induced apoptosis and underscore the relevance of its modulation by HSP70.
Results and discussion
HSP70 specifically associates with AIF and hinders AIF from translocating to the nucleus We have previously shown by coimmunoprecipitation studies that AIF interacted with HSP70, but not with HSP90, HSP60 or HSP27 . In order to evaluate the physiological relevance of this association, we studied whether HSP70 interacted with AIF in vivo. We immobilized the active recombinant AIF protein on a column, followed by the affinity of chromatographic retention of proteins from brain cytosol. The AIF-binding proteins were then eluted and subjected to LC-tandem mass spectroscopy (MS/ MS). The purification conditions used with this unbiased technology allowed the identification of 11 different peptides corresponding to HSP70 (Table 1) . However, no peptides corresponding to any other HSP family member were found, indicating that within complex protein mixtures, AIF can interact with several members of the HSP70 family. This finding further underlines the specificity of the interaction between AIF and HSP70 .
To gain insights into how HSP70 can inhibit AIF apoptotic activity, we studied the effect of HSP70 on the subcellular localization of AIF. Mouse embryo fibroblasts (MEF) stably transfected with inducible HSP70 cDNA (MEF-70) or an empty vector as control (MEFCo) were treated with the universal apoptosis inducer staurosporine (STS). The expression levels of HSP70 and HSP90 in these transfected cells are shown in Figure 1a . Both immunofluorescence microscopy ( Figure 1b ) and cellular fractionation (Figure 1c ) demonstrated that the nuclear translocation of AIF was strongly inhibited by HSP70. The amount of AIF contained in the nuclear fraction of control cells strongly Heat shock proteins eluting from an AIF D1-100 affinity purification column at 4300 mm NaCl identified by LC-tandem mass spectrometry MS/MS AIF nuclear import inhibition by HSP70 S Gurbuxani et al increased after STS treatment, while it remained practically unchanged in HSP70 overexpressing MEF (Figure 1c ). In the same experiments, HSP70 did not affect the mitochondrial release of AIF accompanying apoptosis. AIF exhibited a punctate cytoplasmic (mitochondrial) distribution in untreated cells, while AIF was found diffusely in the cytosol after STS treatment, irrespective of the level of HSP70 expression ( Figure 1b) . As shown in Figure 1d , the HSP70-mediated inhibition of AIF nuclear translocation correlated with cell death inhibition. In conclusion, HSP70 specifically interacts with AIF in the cytosol, thereby hindering AIF to reach its site of action, the nucleus.
Loss of HSP70 binding results in a gain-of-function phenotype
Among a panel of AIF deletion mutants, only mutants lacking the region comprised between amino acids 150 and 228 lost the ability to associate with HSP70 ( Figure  2a and b). We therefore conclude that the HSP70-binding domain of AIF is included between amino acids 150 and 228. To measure the cytotoxic potential of the AIF mutants, MEF cells were transfected with GFP alone (control) or GFP-tagged AIF mutants. At 24 h after transient transfection, cells were either left untreated or were treated with STS (100 nm) for 24 h. Then, cells were stained with the vital dye propidium iodide, and cell death was measured by cytofluorometry, while gating on the transfected GFP þ population. In these conditions, all the plasmids, including wild-type (Wt) AIF, displayed less than 5% autonomous cytotoxicity. This is probably due to the presence of the MLS (Loeffler et al., 2001) (residues 1-100), which attenuates the apoptogenic function of AIF by favouring its mitochondrial retention. However, strong differences were observed after treatment with STS, which induces the mitochondrial release of AIF. Transfection with Wt AIF-GFP sensitized to STS, as compared to transfection with GFP only. Transfection with deletion mutants that fail to bind to HSP70 (AIFD150-268 and AIFD122-262) resulted in a more pronounced sensitizing effect than AIF-Wt ( Figure 2c ). We next studied a point mutant generated in a recently published AIF crystallographic study (Ye et al., 2002) . The mutations of R192AK194A fall into the region defined as being necessary for HSP70 association. Accordingly, R192AK194A abolished the interaction with HSP70 (Figure 2a and b) . This was not due to the absence of the 1-100 N-terminal sequence of AIF, since we have previously demonstrated that this region, necessary for AIF mitochondrial localization but not for its apoptotic function, does not affect the association of HSP70 to AIF or the resulting neutralizing effect of AIF by HSP70 Figure 2b) . As a result of the inability to bind HSP70 (Figure 2b ), R192AK194A displayed a gain-of-function phenotype as compared to Wt AIF ( Figure 2c ). When we determined the AIF nuclear translocation in all these gain-of-function mutants (AIFD150-268, AIFD122-262 and R192A K194A), we found that AIF nuclear translocation was (Figure 2c ). Altogether, these findings underscore the fact that mutation of the HSP70-binding domain of AIF facilitated the nuclear translocation of AIF, thereby increasing its apoptotic function.
Mapping of other AIF domains involved in AIF nuclear translocation and/or apoptotic activity
We next measured the cytotoxic potential of other AIF mutants retaining the capacity to bind HSP70. We found that the frequency of cell death among STS-treated cells transfected with deletion mutants AIFD228-237, AIFD228-347, AIFD263-399, AIFD322-333 and AIFD459-466 was similar to that observed with the Wt-AIF construct (Figure 3a) . However, AIFD567-609 failed to sensitize to STS-induced cell death. Conversely, AIFD367-466 showed increased cell death after STS treatment (Figure 3a ). All the mutants had a capacity to translocate to the nucleus similar to that of Wt-AIF, with the sole exception of mutant AIFD367-466 that lost its nuclear translocation abilities (Figure 3b ). Since AIFD459-466 did translocate to the nucleus, we conclude that a sequence necessary for AIF nuclear localization is comprised between amino acids 367 and 459. In spite of its cytosolic localization, mutant AIFD367-466 had a significant cytotoxic potential and caused nuclear chromatin condensation (Figure 3a) . Figure 4 illustrates by microscopic analysis the different phenotypes obtained: the gain of function represented by AIFD150-268 mutant, the mutant AIFD567-609 that lost the chromatin-condensing activity but not the capacity to Altogether, the functional analysis of the deletion mutants indicates the existence of at least three distinct domains in the AIF protein, namely (1) a region between amino acids 150 and 228 which binds HSP70, (2) a domain between residues 367 and 459 that includes an NLS and (3) a C-terminal domain included between amino acids 567 and 609, required for its chromatincondensing activity.
Contribution of HSP70 binding to AIF-mediated cytotoxicity
To determine the impact of the HSP70-binding site of AIF on nuclear import and AIF-mediated cell killing, we comparatively assessed the cytotoxic effect of different AIF deletion mutants on control MEF, MEF engineered to overexpress HSP70 (MEF-70) and MEF originating from mice deficient for the two genes that code for inducible HSP70 (HSP70.1, HSP70. If HSP70 inhibits apoptosis by withholding AIF in the cytosol (Figure 1, see above) , then we would expect that the subcellular localization of those AIF mutants that fail to interact with HSP70 would not be influenced by the HSP70 expression level. Accordingly, AIFD150-268 ( Figure 6 ) and AIFD122-262 (not shown) exhibited an identical pattern of nuclear import in HSP70-overexpressing and HSP70.1 À/À HSP70.3 À/À MEF. In contrast, the subcellular localization of HSP70-interacting AIF derivatives (Wt AIF, AIFD228-237, AIFD228-347, AIFD322-33, AIFD367-466, AIFD459-466, AIFD567-609) was profoundly influenced by the expression level of HSP70, meaning that HSP70 reduced their nuclear import (Figure 6 ). Interestingly, the nuclear import of the mutant that lacked the 367-459 NLS-containing region (AIFD367-466) was completely abolished in HSP70-expressing cells (Figures 3c and 6a ), yet partially re-established in HSP70.1 À/À HSP70.3 À/À cells ( Figure 6b ). Altogether, these data indicate that the nuclear translocation of AIF is regulated by HSP70 by virtue of its capacity to interact with AIF. The HSP70-mediated inhibition of the AIF translocation was not only detectable with exogenous (GFP-tagged) AIF (Figure 6 ), but also for endogenous AIF detected with a specific antibody. As shown in Figure 7 , the nuclear translocation of endogenous AIF induced by STS was strongly facilitated in the HSP70 knockout cells. Altogether, these data underscore the functional importance of the HSP70-AIF interaction, which determines the cytotoxic potential of AIF.
Concluding remarks
HSPs are important modulators of the apoptotic process. Among these proteins, HSP70 has been probed to be a strong cell death-inhibitory factor that protects against a cornucopia of stressful stimuli . HSP70 inhibits the cytochrome c-dependent apoptotic pathway (Beere et al., 2000) . Moreover, HSP70 inhibits the AIF-dependent apoptotic pathway . In the present work, we dissected the fine mechanisms of HSP70-mediated inhibition AIF-dependent cell death. Recent data based on the crystallographic structure of AIF suggest that AIF has to move to the nucleus to exert its apoptotic activity. Indeed, AIF can interact with DNA, and mutations that block this interaction prevent AIF from inducing the chromatin condensation characteristic of apoptotic death (Ye et al., 2002) . In this work, we mapped the functional regions of AIF involved in its apoptotic function. The first region spans from amino acids 150 to 228 and is required for HSP70 binding and indirectly regulates the nuclear translocation of AIF. Deletion of this region levies inhibition by HSP70 and thus indirectly facilitates the nuclear translocation in HSP70-expressing cells. Provided that HSP70 is present in the cells, this mutation thus results in a gain-of-function phenotype. The second region includes amino acids 367-459. This region, which contains a consensus NLS, is directly involved in AIF nuclear translocation. In fact, AIF contains two consensus NLS sequences (residues 277-301 and 445-451) (Susin et al., 1999) , but the deletion mutants presented in this work demonstrate that the more Cterminal consensus NLS sequence is functionally more important than the more N-terminal one. However, deletion of the 445-451 NLS only partially inhibited AIF import in HSP70.1 À/À HSP70.3 À/À MEF cells, suggesting that this region is not solely responsible for AIF import. The third region that we mapped within the AIF protein is the C-terminal domain beyond residue 567. This region is required for AIF chromatincondensing activity, once AIF is in the nucleus.
HSPs constitute promising therapeutic targets for anticancer therapy. Clinical trials using a specific inhibitor of HSP90, 17-allylamino-17-demethoxygelda- À/À , 70.3 À/À ) (c) were transiently transfected with a vector containing only GFP or with the indicated GFP-tagged AIF plasmids. At 24 h after transient transfection, cells were treated with STS (100 nm, 24 h), stained with vital dye propidium iodide, and cell death was measured by cytofluorometry while gating on the GFP þ population. The values in each panel (X7s.d., n ¼ 3) were normalized with respect to controls with a vector containing GFP only namycin, are currently being performed with encouraging results (Munster et al., 2001) . We and others have recently shown that downregulation of HSP70 with antisense constructs sensitizes to apoptosis induction and even can induce spontaneous cell death (Nylandsted et al., 2000; Gurbuxani et al., 2001) . At least part of the cytoprotective action of HSP70 is mediated by its interaction with AIF, which does not depend on its chaperone activity. With this in mind, an alternative strategy could consist in the use of agents that selectively neutralize the HSP70-AIF interaction, yet have no effect on the chaperone function of HSP70. We are presently exploring the possibility of setting up a highthroughput screening assay, designed to identify small compounds that inhibit the HSP70-AIF interaction. On theoretical grounds, such compounds would act as inhibitors of an apoptosis inhibitor and thus would facilitate apoptosis induction in HSP70-overexpressing cells.
Materials and methods

Cells, culture, vector and transfection
MEFs were grown in DMEM medium (Sigma-Aldrich, Saint Quentin Fallavier, France) supplemented with 10% (v/v) foetal bovine serum (FBS), 1 mm sodium pyruvate and 10 mm HEPES buffer. We recently described stable transfectants of MEF cells carrying the gene encoding human HSP70 . One of the characterized clones (clone 7) was used in this work. Work with knockout mice for hsp70-1 and 70-3 was carried out at the National Health and Environmental Effects Research Laboratory of the US EPA (Research Triangle Park, NC, USA) in accordance with the guidelines of the Animal Care and Use Committee of the US EPA, and with the 'Guide for the Care and Use of Laboratory Animals' published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Briefly, the hsp70-1 and 70-3 genes were targeted in AB2.2 embryonic stem cells derived from mouse strain 129Sv/Ev (Lexicon Genetics, Woodlands, TX, USA). The targeting vector was transfected by electroporation, and homologous recombination resulted in a 12 kb deletion of both hsp70-1 and hsp70-3 coding regions, and insertion of a neomycin resistance gene. The targeted allele was confirmed by Southern blot hybridization of genomic DNA from the stem cells. A male chimaera derived from microinjection of these targeted stem cells into blastocysts from C57BL/6N mice was bred to C57BL/6N females. Agouti coat colour for one male offspring indicated germ-line transmission, and heterozygosity for the hsp70-1/3 targeted allele was confirmed by Southern blot. This F1 C57/129 hybrid was bred back to one of his own heterozygous female offspring to generate homozygous nulls and normalize the hybrid genetic background as much as possible. MEFs explanted from day 13 wild-type or hsp70-1/3 embryos were passaged once a week (6-8000 cells/cm 2 ) with a change of medium on day 3 until they reached senescence. Senescent cells were maintained by medium change twice a week and passaging was restarted upon immortalization.
The AIF-GFP pcDNA3 construct has been described previously (Loeffler et al., 2001) . The deletions described in this paper were performed using the QuickChange Sitedirected and the Ex-site Mutagenesis kits (Stratagene, La Jolla, CA, USA). Cells (4 Â 10 5 /well) were seeded onto six-well plates, 1 day prior to transfection. Transient transfections were carried out using Superfect reagent (Qiagen, Courtaboeuf, France) according to the manufacturer's protocol.
Preparation of AIF-interacting proteins and LC-MS/MS
Recombinant mouse AIF protein lacking the N-terminal 100 amino acids was purified as described (Susin et al., 1999) , activated with phenyldiboronic acid N-hydroxysuccinimide ester and immobilized on an SHA Sepharose s resin (InVitrogen, Carlsbad, CA, USA), following the manufacturer's indications. The column was then loaded with cytosolic proteins prepared from rat brain extracts (Marzo et al., 1998) , extensively washed with 100 mm NaHCO 3 buffer (pH ¼ 8) plus an incremental increase in NaCl concentration up to 500 mm, followed by elution with 100 mm NaHCO 3 (pH ¼ 8), 1 m NaCl. Eluted proteins (4 ml; 8.75 mg/ml) were buffer exchanged and concentrated, using a Centricon YM-3 (3 K cutoff), into 80 mm Tris-HCl, pH 7.5/8 m urea. Only 12 bands were visualized by Coomasie blue staining. These retained proteins were reduced with 5 mm DTT for 30 min at 371C, then carboxyamidomethylated with 10 mm iodoacetamide for 30 min at room temperature in the dark. The sample was diluted fourfold with water, then digested overnight with 0.75 mg trypsin at 371C. Aliquots of the digest were analysed by LC-MS/MS using a Hewlett-Packard 1100 HPLC system (Hewlett-Packard, Palo Alto, CA, USA) connected to a Finnigan LCQ ion-trap mass spectrometer (Thermoquest, San Jose, CA, USA). A C18 column (0.3 mm Â 100 mm) was used for peptide separation (Higgins Analytical, Mountain View, CA, USA). MS/MS spectra were searched against inhouse nonredundant protein sequence databases (Courchesne et al., 1998) .
Cytometric and fluorescence microscopic analyses
Transiently transfected cells were treated or untreated with STS for 24 h. Cell death was measured in transfected cells after propidium iodide staining of nonpermeabilized cells. In all, 10 000 cells were analysed using a FACS Scan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA) and the percentage of cell death was measured in GFP-labelled cells using two-colour flow cytometry. A Leitz microscope equipped with an epi-illuminator and appropriate filters (Leica, Bron, France) was used for immunofluorescence and morphological studies. Double immunofluorescence staining of endogenous AIF and mtHSP70 was performed in whole cells fixed in 3% Castedo et al., 2001) . Appropriate concentrations of antibodies were added simultaneously to the cells in 100 ml of PBS-BSA. After 1 h of incubation at room temperature and two washes, cells were incubated with 488-Alexa (green) goat anti-rabbit and 568-Alexa (red) goat anti-mouse antibodies (Molecular Probes). The slides were washed three times with PBS and covered with coverslips. Subcellular localization of Wt AIF-GFP and mutants and chromatin condensation with or without an apoptotic stimulus was performed after transient transfection. Cells (4 Â 10 5 ) were seeded onto Lab-Tek 8-chamber slides 1 day prior to transfection. Cells were treated or untreated with STS 24 h after transfection. The subcellular localizations of GFP and chromatin condensation were determined as follows. Cells were washed once with PBS, fixed with 3% PFA and stained with Hoechst 33342 (1 mg/ml) for 30 min at 371C. A total of 300 GFP-expressing cells were counted to determine the subcellular localization of AIF and the frequency of apoptosis. The level of GFP fluorescence in the transfected cells was similar for all the mutant proteins analysed (mean fluorescence index 127710).
Immunoblot analysis
Whole-cell lysates were prepared by lysing the cells in 2% SDS, 137 mm NaCl, 2.7 mm KCl, 8 mm Na 2 HPO 4 and NaCl/Pi (pH 7.4) at 681C for 5 min. Protein concentration was measured by means of the micro-BCA protein assay (Pierce, Asnie`res, France). Proteins were separated in 8-12% SDS-polyacrylamide gel and electroblotted onto PVDF membranes (BioRad, Ivry sur Seine, France). Immunoblot analysis was performed using specific antibodies and enhanced chemoluminescence (ECL)-based detection (Amersham, Buckinghamshire, UK, Les Ullis, France). The antibodies used were the mouse monoclonal anti-human HSP70, HSP90, mtHSP70 and polyclonal anti-human HSP70 (StressGen, Victoria, Canada) and rabbit polyclonal antibodies raised against human AIF (PharMingen, Erembodegem, Belgium).
Cell fractionation and immunoprecipitation in cell-free extracts
Protein-protein interactions between the Wt-AIF or the AIF mutants and HSP70 were determined by immunoprecipitation experiments in nuclei-free, mitochondria-free cytosolic extracts from MEF-70 cells in which the in vitro translated tagged AIF protein had been added. In vitro translation of the His-V5 or GFP-tagged Wt-AIF and mutant AIF was performed using the TNT-coupled reticulocyte lysate systems (Promega, Charbonnie`res, France). b-gal tagged with the His-V5 epitope was used as a negative control for the immunoprecipitation reactions. The nuclei-free, mitochondria-free extracts were prepared as described (Garrido et al., 1999) . Briefly, cells were washed in ice-cold PBS, pH 7.2, then in hypotonic extraction buffer (HEB: 50 mm PIPES, pH 7.4, 50 mm KCl, 5 mm EGTA, 2 mm MgCl 2 , 1 mm dithiothreitol and 0.1 mm phenylmethylsulphonyl fluoride) and centrifuged. The pellet was resuspended in HEB and lysed in a Dounce homogenizer. This cell lysate was centrifuged for 30 min at 16 000 g at 41C, and the clarified supernatant was either tested immediately or stored in aliquots at À801C. For immunoprecipitation, 50 ml of the cell-free extract was incubated with 20 ml of the reticulocyte lysate for each of the IP reactions at room temperature for 30 min. Immunoprecipitations were subsequently performed in a final total volume of 500 ml of IP buffer (50 mm HEPES pH 7.6, 150 mm NaCl, 5 mm EDTA, 0.1% NP-40) with a polyclonal anti-human HSP70 antibody (1 : 100) with constant agitation at 41C. The immunocomplexes were precipitated with protein A Sepharose (Amersham, Buckinghamshire, UK). The pellet was washed five times and prepared for immunoblotting.
Cytosolic and nuclear fractions for AIF studies were prepared by resuspending cells in ice-cold buffer A (250 mm sucrose, 20 mm HEPES, 10 mm KCl, 1.5 mm MgCl 2 , 1 mm EDTA, 1 mm EGTA, 1 mm DTT, 17 mg/ml PMSF, 8 mg/ml aprotinin, 2 mg/ml leupeptine (pH 7.4)). Homogenization was performed in a Potter-Thomas homogenizer. Nuclei were pelleted via a 10 min, 750 g spin. The supernatant was spun at 10 000 g for 25 min and the mitochondrial fraction was resuspended in buffer A.
